Immune cell therapy for recurrent malignant brain tumor
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental immune cell therapy for a type of brain tumor called malignant meningioma that has come back after standard treatment. The goal is to see if these special immune cells can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- You have been diagnosed with a malignant (cancerous) brain tumor called meningioma
- Your tumor has come back after prior treatment
- You have finished chemotherapy or targeted therapy at least 4 weeks ago
- You are generally well enough to carry out daily activities (ECOG 0-2)
- Your heart, liver, kidney, and blood function are within trial limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial tests a new type of immune therapy using special T cells (a kind of white blood cell) given directly into the brain tumor area. It's for patients with a severe brain tumor that hasn't improved with standard treatments.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to attack brain tumor cells and also blocks a protein (PD-L1) that helps the tumor hide from your immune system. It is for people with a recurrent malignant glioma, a serious brain tumor that has returned despite prior treatment.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
Hear when a new Malignant Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.